v3.19.3
Consolidated Balance Sheets - USD ($)
Sep. 30, 2019
Dec. 31, 2018
Current Assets    
Cash and cash equivalents $ 9,334,421 $ 22,154,251
Short-term investments 5,683,446 5,570,027
Accounts receivable 37,300 28,538
Prepaid expenses and other current assets 734,788 961,317
Total Current Assets 15,789,955 28,714,133
Property and Equipment, net 609,916 643,146
Other Assets    
In-process R&D 5,866,000 5,866,000
Goodwill 1,452,338 2,189,338
Right-of-use asset 347,153
Deposits 386,284 351,220
Total Other Assets 8,051,775 8,406,558
Total Assets 24,451,646 37,763,837
Current Liabilities    
Accounts payable 1,944,333 974,619
Deferred revenue 1,032,539
Contingent consideration, current portion 1,477,000 1,187,000
Operating lease liability, current portion 91,068
Accrued expenses and other liabilities 1,281,911 1,678,051
Total Current Liabilities 4,794,312 4,872,209
Long Term Liabilities    
Contingent consideration 2,356,515 1,918,225
Deferred tax liability 361,911 316,733
Deferred revenue, net of current portion 200,000 200,000
Operating lease liability, net of current portion 259,222
Other long-term liabilities 306,235 213,724
Total Liabilities 8,278,195 7,520,891
Commitments and Contingencies
Stockholders' Equity    
Common stock, $.0002 par value; 100,000,000 shares authorized, 33,334,124 and 32,492,144 shares issued and outstanding at September 30, 2019 (unaudited) and December 31, 2018, respectively 6,822 6,499
Additional paid-in capital 117,836,082 114,883,135
Accumulated deficit (101,261,124) (84,580,180)
Accumulated other comprehensive loss 52,230 (19,904)
Total Stockholders' Equity-Heat Biologics, Inc. 16,634,010 30,289,550
Non-Controlling Interest (460,559) (46,604)
Total Stockholders' Equity 16,173,451 30,242,946
Total Liabilities and Stockholders' Equity $ 24,451,646 $ 37,763,837

Source